创业慧康近两年亏3亿拓展新业务破局 港股华检医疗5亿“H吃A”推进AI战略
Chang Jiang Shang Bao·2025-11-18 23:40

Core Viewpoint - The acquisition of Chuangye Huikang (创业慧康) by Huajian Medical (华检医疗) marks a significant move in the healthcare sector, aiming to leverage Chuangye Huikang's extensive industry experience and AI capabilities to enhance Huajian Medical's strategic positioning in AI healthcare [1][6]. Group 1: Acquisition Details - Huajian Medical will acquire control of Chuangye Huikang through a three-step process, starting with the transfer of 96.52 million shares from the original major shareholder, Ge Hang, to Hangzhou Genghao, representing 6.23% of the total share capital at a price of 5.18 yuan per share, totaling 500 million yuan [2][3]. - Following the share transfer, Hangzhou Genghao will receive voting rights for an additional 99.26 million shares, increasing its total voting power to 12.64% of Chuangye Huikang's total share capital [2][4]. - The final step involves recommending new board members, which could lead to a change in control of Chuangye Huikang if the proposed directors are elected [4]. Group 2: Financial Performance - Chuangye Huikang has faced declining financial performance, with a reported revenue of 8.62 billion yuan in the first three quarters of 2025, a decrease of 26.26% year-on-year, and a net loss of 1.22 billion yuan, marking a 331.69% decline [1][7]. - The company has experienced cumulative net losses of 296 million yuan over the past two years, with significant declines in both revenue and net profit since 2021 [7][8]. - Despite the challenges, Chuangye Huikang has secured 24 orders worth over 10 million yuan each, with a 20% increase in order quantity and a 7% increase in order value year-on-year [8]. Group 3: Strategic Rationale - Huajian Medical views the acquisition as a strategic move to capitalize on Chuangye Huikang's nearly 30 years of industry experience and its forward-looking AI initiatives, positioning itself to lead in the rapidly growing AI healthcare market [6][7]. - The integration aims to create a new paradigm in AI healthcare, leveraging both companies' strengths to enhance competitiveness in the industry [6].